Patients can turn off an experimental treatment if side effects get too bad.
Susan YoungFollow @twitterapi
I’m the biomedicine editor for MIT Technology Review. I look for stories where technology stands to improve human health or advance our understanding of the human condition.
I joined MIT Technology Review in March 2012 after a brief stint in the Washington, D.C., news bureau of the scientific journal Nature. Before I ventured to the East Coast, I spent several years in the San Francisco Bay Area as a doctoral student in molecular biology and one whirlwind year in science-writing boot camp in Santa Cruz.
In California, I wrote for the Stanford University press offices, the Multiple Sclerosis Discovery Forum, and the Salinas Californian newspaper. I grew up in a small town in eastern Texas, surrounded by bird song, rolling cattle fields, and lanky pine trees. When I’m not exploring health tech, you will probably find me cooking or giggling over an exceptional LOLcat.
Susan Young's Stories
A light-sensitive polymer could offer a new way to develop artificial retinas.
Early treatment may be key to a drug-free life for a small percentage of patients.
Sorting concussion patients based on internal brain injury could help doctors identify those with more severe cases.
Broadband communication and custom signal-processing chips power a new brain-recording device that may one day help paralyzed people.
Illumina will work with SynapDx's to find a blood-test that could allow treatment to start earlier.
Researchers explain the goals and structure of a new brain-mapping project.
Brain wave patterns show a clear transition to a coma-like state in patients under general anesthesia.
An accidental discovery in pediatric HIV treatment may one day save others born into infection.
The FDA looks into the safety of the da Vinci system in light of increased adverse incidents.